Loading clinical trials...
Loading clinical trials...
Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.
Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or greater were treated with metformin up to 2500 mg/day in an open label study of up to 3 months time. Changes in weight and glucose measures were recorded.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Manhatan Psychiatric Center
New York, New York, United States
Start Date
May 1, 2008
Primary Completion Date
April 1, 2011
Completion Date
April 1, 2011
Last Updated
September 1, 2017
12
ACTUAL participants
Metformin
DRUG
Lead Sponsor
Nathan Kline Institute for Psychiatric Research
NCT07472881
NCT01143454
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions